IMS Health put itself up for sale, according to several reports citing people familiar with the matter. According to a Wall Street Journal report, the offers – from TPG, Silver Lake and BC Partners – are expected to give IMS stockholders a 30% premium on their shares, valuing the company at approximately $3.5 billion. Shares were up 21.6% - to $17.84 – following the WSJ report yesterday afternoon.
Bristol-Myers Squibb will cut roughly 25% of its Abilify sales force, according to a Bloomberg report. The cuts are a result of Otsuka Pharmaceuticals, a partner on the antipsychotic drug, taking over more of the marketing duties on Abilify, according to the report.